Anavex Life Sciences Advances Parkinson’s Treatment with Promising New Findings
Anavex Life Sciences has unveiled encouraging data from its 48-week Phase 2 extension study on ANAVEX®2-73 for treating Parkinson’s disease dementia. This pioneering study highlights the potential therapeutic benefits of ANAVEX®2-73, advancing hopes for improved management of this challenging condition. Conducted over nearly a year, the trial evaluated ANAVEX®2-73’s impact on patients’ cognitive and motor […]
Read More